New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
December 19, 2014
11:32 EDTPFELigand reports Pfizer receives EU marketing authorization for Duavive
Ligand Pharmaceuticals (LGND) announced that its partner Pfizer (PFE) has received EU marketing authorization for DUAVIVE from the European Commission. In the EU, DUAVIVE is indicated for the treatment of estrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestin-containing therapy is not appropriate. Ligand will be entitled to a milestone payment following Pfizer obtaining pricing of DUAVIVE in a major European market, the company stated.
December 18, 2014
12:55 EDTPFECourt delays Teva's launch of generic Celebrex, Globes reports
Subscribe for More Information
11:08 EDTHLFOptions with increasing implied volatility
Options with increasing implied volatility: CZR RSX HLF YPF ARCP MGM A MCD
08:03 EDTPFEPfizer reports statistically significant results in Phase 3 pregabalin study
Pfizer announced top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release formulation in adult patients with postherpetic neuralgia. The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response in pain reduction. PHN is a type of peripheral neuropathic pain caused by nerve damage. Symptoms include continued burning or electric shock-like pain.1 This study is the final of three Phase 3 studies of the pregabalin CR formulation conducted to ascertain the potential use of pregabalin as a once-a-day therapy. The first study in adults with partial onset seizures with epilepsy did not meet its primary endpoint. In the second study in patients with fibromyalgia, pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to LTR in pain reduction. The objective of the Phase 3 double-blind, randomized, placebo-controlled study was to evaluate the safety and efficacy of pregabalin CR compared with placebo in the durability of effect for the treatment of pain associated with PHN among patients who initially respond to single-blind pregabalin.
07:29 EDTCALMCal-Maine Foods volatility elevated into Q2 and booking outlook
Subscribe for More Information
07:28 EDTPFEPfizer shares poised to perform well in 2015, says Deutsche Bank
Subscribe for More Information
December 17, 2014
11:38 EDTHLFOptions with increasing implied volatility
Subscribe for More Information
10:50 EDTHLFHerbalife salesman calls admits company 'deception' in video, NY Post reports
Subscribe for More Information
10:45 EDTHLFAckman says Herbalife 'implosion' a likely 2015 event
Pershing Square's Bill Ackman is speaking on Bloomberg TV.
10:45 EDTHLFAckman says Icahn 'stuck holder' of Herbalife due to board position
Subscribe for More Information
10:44 EDTHLFAckman says Herbalife about 7% position in fund
Pershing Square's Bill Ackman is speaking on Bloomberg TV.
10:43 EDTHLFAckman says government 'closer' to intervening in Herbalife
Subscribe for More Information
10:42 EDTHLFAckman says continues to believe Herbalife shares worth zero
Subscribe for More Information
10:42 EDTHLFAckman says Herbalife Q4 results will be worse than Q3
Subscribe for More Information
10:41 EDTHLFAckman says Herbalife business deteriorating
Subscribe for More Information
10:19 EDTHLFHerbalife January and February volatility elevated, shares near 18-month low
Herbalife December call option implied volatility is at 54, January is at 71, February is at 86; compared to its 26-week average of 61 according to Track Data, suggesting large near term price movement.
09:33 EDTCALMCal-Maine Foods upgraded to Buy from Neutral at Sidoti
Subscribe for More Information
08:01 EDTPFEPfizer initiates Phase 2 PF-06252616 study
Subscribe for More Information
December 16, 2014
17:37 EDTCGCarlyle Group puts ITS Technologies & Logistics up for sale, WSJ says
Subscribe for More Information
08:47 EDTBMYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
06:03 EDTHLFHerbalife insider trading case dismissed by SEC, NY Post reports
Subscribe for More Information
December 15, 2014
18:32 EDTPFEPfizer announces Palbociclib PALOMA-1 data published in The Lancet Oncology
Subscribe for More Information
12:09 EDTPFEPfizer increases dividend 8% to 28c per share
Subscribe for More Information
10:40 EDTPFEOPKO Health deal with Pfizer removes financing overhang, says Ladenburg
Ladenburg views the agreement OPKO Health (OPK) signed with Pfizer (PFE) as a significant positive catalyst since the company is partnering with an established leader in short-acting hGH and because the large upfront payment removes near-term financing needs as an overhang on the stock. The firm reiterates its Buy rating and $14.50 price target on OPKO, but said it will re-examine its projections after the deal closes.
10:19 EDTPFEOPKO Health soars after entering hGP-CTP agreement with Pfizer
Subscribe for More Information
10:00 EDTCGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:03 EDTPFEBaxter to divest Vero cell vaccines platform to Nanotherapeutics
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed. The agreement with Nanotherapeutics includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza. The agreement also includes investigational vaccine programs for Ross River virus, Chikungunya disease and West Nile virus. In recent weeks, the company has also completed the sale of its commercial vaccines business and related manufacturing facilities to Pfizer (PFE).
08:19 EDTCGCarlyle Group initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information
08:02 EDTPFEPfizer, OPKO Health enter into global agreement for hGH-CTP
Subscribe for More Information
December 11, 2014
09:35 EDTHLFHerbalife says product claims have 'strict rules and guidelines'
Subscribe for More Information
09:34 EDTHLFVideo entitled 'Harmful Promises' posted to Ackman's Herbalife website
Subscribe for More Information
December 10, 2014
08:31 EDTPFETeva announces launch of first generic Celebrex capsules in the U.S.
Teva Pharmaceutical Industries (TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. Celebrex Capsules, marketed by Pfizer (PFE) had annual sales of approximately $2.56B in the United States, according to IMS data as of October 2014.
07:38 EDTPFEMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
06:08 EDTBMYBristol-Myers partners with Ono Pharma and Kyowa Hakko Kirin for oncology trial
Subscribe for More Information
December 9, 2014
16:35 EDTBMYBristol-Myers raises dividend to 37c per share from 36c per share
Subscribe for More Information
12:22 EDTPFEPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:32 EDTPFEPfizer says in talks with FDA on path forward for Mylotarg
Pfizer announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate MYLOTARG in select adult AML populations. Research was presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, December 6-9. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology, said “In particular, we are encouraged by the significant clinical evidence emerging from large randomized trials, such as AML-19 and ALFA-0701, demonstrating a positive impact of MYLOTARG when added to standard first-line treatment for patients with acute myeloid leukemia. We are engaging in discussions with the U.S. FDA and other health authorities to determine the best path forward for MYLOTARG. In addition, we plan to initiate an expanded access protocol for the therapy by the end of 2014 in the United States in patients with relapsed or refractory acute myeloid leukemia for whom there are no other treatment options.”
08:25 EDTBMYBristol-Myers data positive, says BMO Capital
Subscribe for More Information
07:44 EDTPFEAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:33 EDTCGCarlyle Group acquires majority stake in Newgen KnowledgeWorks for $32.8M
The Carlyle Group has invested $32.8M to acquire a 54.85% stake in Chennai, India-based Newgen KnowledgeWorks Private Limited, a provider of publishing and technical services for many of the world’s largest and most prestigious publishers, particularly in the USA, the UK and Europe. Equity for the transaction comes from First Carlyle Ventures III, an investment fund advised by The Carlyle Group. Carlyle acquired the stake held by Franklin Templeton Private Equity Strategy, Aureos South Asia Fund and ePlanet Capital in Newgen. Carlyle had earlier invested in Newgen in 2004 and exited its investment in 2011.
December 8, 2014
13:32 EDTBMY, PFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
14:10 EDTBMYAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use